Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2022 / Cilt: 46 - Sayı: 2

TREATMENT OF BEHÇET’S DISEASE AND CURRENT APPROACHES

BEHÇET HASTALIĞININ TEDAVİSİ VE GÜNCEL YAKLAŞIMLAR

Pages
619–650
Publication Date
2022-05-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review is presented to bring together the specific treatment procedures applied during the progression of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Behçet's Disease (BD) is a multisystemic inflammatory disease which courses with relapses and characterized by four major symptoms of oral aphthous ulcers, genital ulcers, skin lesions and ocular lesions; and five minor symptoms including joint involvement, gastrointestinal ulcers, epididymitis, vascular lesions and neurological involvement.
📊
Key Findings & Data:Treatment in BD varies according to the clinical course of age at which the disease begins, gender, the organs involved and the clinical course of the disease; therefore, it should be performed according to the person and the symptoms.
💡
Conclusion & Impact:This review is presented to bring together the specific treatment procedures applied during the progression of the disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Behçet Hastalığı · glukokortikoidler · anti-TNF-α

Abstract

Objective: Behçet's Disease (BD) is a multisystemic inflammatory disease which courses with relapses and characterized by four major symptoms of oral aphthous ulcers, genital ulcers, skin lesions and ocular lesions; and five minor symptoms including joint involvement, gastrointestinal ulcers, epididymitis, vascular lesions and neurological involvement. Treatment in BD varies according to the clinical course of age at which the disease begins, gender, the organs involved and the clinical course of the disease; therefore, it should be performed according to the person and the symptoms. While empirical treatment of BD is still continuing; recently, effective protocols have been implemented due to the pathogenesis of the underlying disease that is better defined and many broad-spectrum therapeutic agents have been presented for the treatment. This review is presented to bring together the specific treatment procedures applied during the progression of the disease.

Özet

Amaç: Behçet Hastalığı (BH), nükslerle seyreden, oral aft, genital ülser, deri lezyonları ve oküler lezyonlar olmak üzere dört majör bulgu ve eklem tutulumu, gastrointestinal ülserler, epididimit, vasküler lezyonlar ve nörolojik tutulum dahil olmak üzere beş minör bulguyla karakterize multisistemik inflamatuar bir hastalıktır. BH' de tedavi hastalığın başladığı yaşa, cinsiyete, tutulan organlara ve hastalığın klinik seyrine göre değişir; bu nedenle tedavi kişiye ve semptomlara göre yapılmalıdır. BH' nin ampirik tedavisi halen devam ederken; son zamanlarda altta yatan hastalığın patogenezinin daha iyi tanımlanması nedeniyle etkili protokoller uygulanmış ve tedavi için birçok geniş spektrumlu terapötik ajan sunulmuştur. Bu derleme, hastalığın progresyonu döneminde uygulanan spesifik tedavi prosedürlerini bir araya getirme hedefiyle ortaya koyulmuştur.

🔖

Cite This Article

ÇAKMAK, G. Y., ŞEHİRLİ, A. Ö. (2022). TREATMENT OF BEHÇET’S DISEASE AND CURRENT APPROACHES. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 46 - Sayı: 2, 619–650. https://ajindex.com/articles/406869

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Referans1. Greco, A., A. De Virgilio, M. Ralli, A. Ciofalo, P. Mancini, G. Attanasio, M. de Vincentiis, and A. Lambiase. (2018). Behçet's disease: new insights into pathophysiology, clinical features and treatment options. J Autoimmunity reviews, 17(6), 567-575. [CrossRef] Referans2. Bulur, I. and M. Onder. (2017). Behçet disease: new aspects. J Clinics in dermatology, 35(5), 421-434. [CrossRef] Referans3. Sakane, T., M. Takeno, N. Suzuki, and G. Inaba. (1999). Behçet's disease. J New England Journal of Medicine, 341(17), 1284-1291. [CrossRef] Referans4. Esatoglu, S.N. and G. Hatemi. (2019). Update on the treatment of Behçet’s syndrome. J Internal emergency medicine, 14(5), 661-675. [CrossRef] Referans5. Quax, R., J. van Laar, R. Van Heerebeek, K. Greiner, E. Ben-Chetrit, M. Stanford, G. Wallace, F. Fortune, M. Ghabra, and M. Soylu. (2012). Glucocorticoid sensitivity in Behçet's disease. J Endocrine connections, 1(2), 103-111. [CrossRef] Referans6. Merashli, M., R. El Eid, and I. Uthman. (2018). A review of current management of vasculo-Behcet's. J Current opinion in rheumatology, 30(1), 50-56. [CrossRef] Referans7. Leung, Y.Y., L.L.Y. Hui, and V.B. Kraus. (2015). Colchicine—update on mechanisms of action and therapeutic uses. Seminars in arthritis and rheumatism, 45(3), 341-350. [CrossRef] Referans8. Slobodnick, A., B. Shah, M.H. Pillinger, and S.J.T.A.j.o.m. Krasnokutsky. (2015). Colchicine: old and new. 128(5), 461-470. [CrossRef] Referans9. Marques‐da‐Silva, C., M. Chaves, N. Castro, R. Coutinho‐Silva, and M.J.B.j.o.p. Guimaraes. (2011). Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor‐expressing cells: implications for its therapeutic action. 163(5), 912-926. [CrossRef] Referans10. Yazici, H., E. Seyahi, G. Hatemi, and Y. Yazici. (2018). Behçet syndrome: a contemporary view. J Nature Reviews Rheumatology, 14(2), 107-119. [CrossRef] Referans11. Yurdakul, S., C. Mat, Y. Tüzün, Y. Özyazgan, V. Hamuryudan, Ö. Uysal, M. Şenocak, and H. Yazici. (2001). A double‐blind trial of colchicine in Behçet's syndrome. J Arthritis Rheumatism, 44(11), 2686-2692. [CrossRef] Referans12. Hatemi, G., R. Christensen, D. Bang, B. Bodaghi, A.F. Celik, F. Fortune, J. Gaudric, A. Gul, I. Kötter, and P.J.A.o.t.r.d. Leccese. (2018). 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. 77(6), 808-818. [CrossRef] Referans13. Takeno, M. (2020). Positioning of apremilast in treatment of Behçet’s disease. J Modern rheumatolo